Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA(TM) in Systemic Lupus Erythematosus
02. November 2009 00:01 ET
|
Human Genome Sciences
ROCKVILLE, MD and LONDON--(Marketwire - November 2, 2009) - Human Genome Sciences, Inc.
(NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab)
met the primary...
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
20. Juli 2009 00:01 ET
|
Human Genome Sciences, Inc.
ROCKVILLE, MD and LONDON--(Marketwire - July 20, 2009) - Human Genome Sciences, Inc.
(NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab,
formerly...